Thyroid Cancer | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2016

From disease basics to insightful analysis of market dynamics, Thyroid Carcinoma | Niche Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing critical aspects of the thyroid carcinoma pharmaceutical market based on detailed primary and secondary market research. Content includes a summary of disease etiology, pathophysiology, and drug targets; epidemiological projections, including estimates of drug treatment; a deep examination of current therapies and medical practice; a review of top unmet needs; a thorough pipeline assessment, including regulatory approval timing, positioning, and peak sales of key late-phase drugs; a top-line review of pertinent market access themes; and an epidemiology-based, bottom-up market forecast of key branded agents with supporting tables, figures, and methods.

Questions Answered:

• The overall thyroid carcinoma population will increase due to improved diagnostic procedures. How large is the drug-treatable thyroid carcinoma population, and how will drug-treatment rates change over time? What are the drivers and constraints in the thyroid carcinoma market?
• While surgery is the mainstay of treatment, four therapies have been approved since 2011 for the treatment of advanced cases of thyroid carcinoma. What is the current state of treatment in thyroid carcinoma? What are the most commonly prescribed drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
• There is only one drug class in late-phase clinical development for thyroid carcinoma, but  there are different drug classes in early-phase development, such as the immunotherapies. What pipeline products are most promising, and what sales/uptake could they secure in thyroid carcinoma? What therapies of note are progressing in earlier phases?
• We have identified several unmet needs and challenges in the thyroid carcinoma landscape. What are the key unmet needs in the treatment of thyroid carcinoma according to interviewed thought leaders? Is it likely that these unmet needs will be addressed or partially addressed during our forecast period?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: 8 country-specific interviews with thought leaders.

Epidemiology: Diagnosed incident cases of thyroid carcinoma (WHO ICD-10 coding system and ICD-O3 histological classification of tumors) by disease stage (stage I, stage II, stage III, stage IVa, stage IVb, stage IVc) and thyroid carcinoma histologies (follicular, papillary, medullary, and anaplastic). Recurrent incident (distant metastatic) cases of thyroid carcinoma.

Population segments in market forecast: Locally advanced radioactive iodine-avid differentiated thyroid carcinoma; locally advanced and metastatic radioactive iodine-refractory differentiated thyroid carcinoma; locally advanced and metastatic symptomatic and/or progressive medullary thyroid carcinoma.

Emerging therapies: Phase III: 1 drug; Phase II: 9 drugs; coverage of selected Phase I products.